Roberts J, Schmid F A, Old L J, Stockert E
Cancer Biochem Biophys. 1976 May;1(4):175-8.
The relative antineoplastic effectiveness of E. coli and Erwinia asparaginases was tested against lymphoid leukemias EARAD-1 and L5178Y/CA55. E. coli and Erwinia asparaginases had similar clearance rates from plasma in mice, and at a dose of 250 IU/kg body weight both enzymes lowered plasma asparagine to undetectable levels. Nevertheless, the dosage of Erwinia asparaginase needed to cause similar prolongation of median survival time in leukemic mice was at least twice that of E. coli asparaginase. The factors which may be responsible for the more potent therapeutic effectiveness of the E. coli asparaginase are discussed.
测试了大肠杆菌天冬酰胺酶和欧文氏菌天冬酰胺酶对淋巴白血病EARAD - 1和L5178Y/CA55的相对抗肿瘤效果。大肠杆菌天冬酰胺酶和欧文氏菌天冬酰胺酶在小鼠血浆中的清除率相似，在250 IU/kg体重的剂量下，两种酶都能将血浆天冬酰胺水平降至检测不到的水平。然而，在白血病小鼠中，要使中位生存时间延长相似所需的欧文氏菌天冬酰胺酶剂量至少是大肠杆菌天冬酰胺酶的两倍。文中讨论了可能导致大肠杆菌天冬酰胺酶具有更强治疗效果的因素。
